anti-CD37 CAR T-cell therapy (CellPoint BV)

N/A

Report date: 2022/07/08 09:39:17

Base Information

Drug Nameanti-CD37 CAR T-cell therapy (CellPoint BV)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-Leukocyte antigen CD37T lymphocyte replacements

TargetsLeukocyte antigen CD37

Therapy Area/IndicationsOvarian NeoplasmsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlandsNorway

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCellPoint BV

China Registration ClassN/A

Develop Information

Active CompaniesCellPoint BV Oslo University Hospital University Of Oslo

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A